Back to Search
Start Over
Prognostic and predictive impact of MGMT promoter methylation in grade 3 gliomas
- Source :
- Journal of Clinical Neuroscience. 85:115-121
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Grade 3 gliomas are aggressive primary brain tumors. Promoter methylation of methyl guanine methyl transferase (MGMT) has been associated with a favorable prognosis in patients with glioblastoma, but the impact of MGMT promoter methylation in patients with grade 3 gliomas is less clear. The purpose of the present study was to evaluate the utilization of MGMT testing in patients with Grade 3 glioma, as well its prognostic and predictive value.The National Cancer Database (NCDB) was queried (2004-2016) for patients with newly diagnosed grade 3 glioma without 1p19q codeletion. Statistics included Kaplan-Meier overall survival (OS) analysis, along with Cox proportional hazards modeling.Of 20,488 total patients, 1,209 (5.0%) had MGMT testing. Of these patients, 561 (46.4%) were MGMT methylated (mMGMT), and 648 (53.6%) were MGMT unmethylated (uMGMT). mMGMT patients experienced greater median overall survival (OS) than both uMGMT patients as well as patients with no MGMT status reported (p 0.05 for both). mMGMT was associated with improved OS for patients receiving adjuvant chemoradiation or adjuvant radiation, but not for patients receiving adjuvant chemotherapy or no adjuvant treatment.This is the largest study to date describing the utilization of and outcomes for mMGMT patients with grade 3 glioma. The present results demonstrate that mMGMT is a prognostic factor and possibly a predictive biomarker, and is currently under-utilized within the US. MGMT methylation status could be used to risk-stratify and select patients for treatment intensification.The present study is the largest of its kind to examine the prognostic and predictive impact of MGMT methylation (mMGMT) amongst patients with Grade 3 Glioma. The results suggest that mMGMT is prognostic, as amongst all patients, mMGMT was associated with improved overall survival. These results also suggest that mMGMT is predictive, as patients treated with adjuvant chemoradiation or adjuvant radiation therapy did have improved overall survival with mMGMT, though there was no difference in overall survival observes amongst patients receiving adjuvant chemotherapy or those patients receiving no adjuvant treatment. The study also found that only 5% of patients nationwide with Grade 3 Glioma are tested for MGMT.
- Subjects :
- Adult
Oncology
medicine.medical_specialty
medicine.medical_treatment
Kaplan-Meier Estimate
03 medical and health sciences
0302 clinical medicine
Physiology (medical)
Internal medicine
Glioma
Promoter methylation
Biomarkers, Tumor
medicine
Humans
In patient
Promoter Regions, Genetic
DNA Modification Methylases
neoplasms
Aged
Aged, 80 and over
Chemotherapy
Brain Neoplasms
Proportional hazards model
business.industry
Tumor Suppressor Proteins
Cancer
General Medicine
DNA Methylation
Middle Aged
Prognosis
medicine.disease
Radiation therapy
DNA Repair Enzymes
Neurology
030220 oncology & carcinogenesis
Female
Surgery
Neurology (clinical)
business
Adjuvant
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 09675868
- Volume :
- 85
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Neuroscience
- Accession number :
- edsair.doi.dedup.....462da109d8d4b4f40effad4f4a102efe